Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Myeloid 1

Conditions

Leukemia, Myeloid, Acute 95Leukemia, Lymphocytic, Chronic, B-Cell 46Lymphoma, Mantle-Cell 16Myelodysplastic Syndromes 15Leukemia 13Leukemia, Biphenotypic, Acute 10Recurrence 9Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 9Neoplasms 9Lymphoma, B-Cell, Marginal Zone 8Waldenstrom Macroglobulinemia 7Precursor Cell Lymphoblastic Leukemia-Lymphoma 7Lymphoma 7Leukemia, Myelomonocytic, Chronic 7Leukemia, Myelogenous, Chronic, BCR-ABL Positive 7Multiple Myeloma 6Lymphoma, Follicular 6Myeloproliferative Disorders 5Lymphoma, Large B-Cell, Diffuse 5Burkitt Lymphoma 5Neoplasm, Residual 4Leukemia, B-Cell 3Chromosome 17 deletion 3Blastic Plasmacytoid Dendritic Cell Neoplasm 3Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 2Lymphoproliferative Disorders 2Lymphoma, T-Cell 2Lymphoma, Non-Hodgkin 2Leukemia, Monocytic, Acute 2Hematologic Neoplasms 2

Interventions

Trastuzumab 5Carboplatin 4toripalimab 2pertuzumab 2pembrolizumab 2Tretinoin 2Paclitaxel 2Immunotherapy 2Drug Therapy 2Doxorubicin 2Docetaxel 2Cytarabine 2130-nm albumin-bound paclitaxel 2zanidatamab 1venetoclax 1veliparib 1tucatinib 1trilaciclib 1trebananib 1trastuzumab duocarmazine 1tislelizumab 1temsirolimus 1talazoparib 1tagraxofusp 1sarilumab 1sargramostim 1pyrotinib 1pexidartinib 1pazopanib 1patritumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Pathologic Complete Response × venetoclax × Clear all
NCT07007052 2025-11-26

TAGVEN

French Innovative Leukemia Organisation

Phase 2 Not yet recruiting
33 enrolled
Myeloid

Pathologic Complete Response, Blastic Plasmacytoid Dendritic Cell Neoplasm

Data powered by HemOnc (CC BY 4.0) Colophon âš¡